For how we live.
Tirzepatide topped weight loss at 14.9%. But only subcutaneous semaglutide showed a mortality benefit — and no drug moved the needle on quality of life or kidney failure.
No study has directly compared injectable tirzepatide with the new high-dose oral semaglutide pill. A statistical technique that adjusts across two separate trials estimates the gap.
A single-clinic retrospective study in Istanbul followed patients on all three drugs for 36 weeks. The ranking matches what randomized trials have shown — with liraglutide the least tolerated of the three.
The trial's own primary outcome — inflammation — was flat. What the new analysis adds is a molecular account of why the fat loss did not translate into the benefits fasting is sold on.